Cancer networks are specific, contextual, dynamic and interactive! The best way to delineate complex cancer networks is to integrate both transcriptomics (mRNA) expression profile as well as miRNA expression profile – this imparts both the functional and regulatory messages in a cancer context. However, recent spate of miRNA analysis in the elucidation of cancer networks suggests specific and distinct advantages of miRNA profiling over mRNA signatures – both biological and technical.
May 12, 2016
Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States. In 2016 about 140,000 people will be diagnosed and 50,000 will die from this disease. On average, the lifetime risk of developing colon cancer is about 5%, however, this varies widely according to individual risk factors. About 72% of cases arise in the colon and about 28% in the rectum. In recent years, introduction of a new adjuvant chemotherapy for patients with stage III colon cancer, was very successful and significantly increased disease-free survival in these patients. However, there was no improvement in disease-free survival for patients with earlier-stage (stage I and II) disease due to the lack of simple, reliable criteria for the identification of patients who are at high risk for relapse. Now, a groundbreaking study published in the New England Journal of Medicine, demonstrated that CDX2 antibodies from BioGenex (Clone CDX2-88) can be employed in a new prognostic approach and help save lives of stage II Colon Cancer patients.
Apr 21, 2016
Urothelial Carcinoma (UCC, also known as transitional cell carcinoma) is a cancer that starts in the urothelial cells, which line the inside of the bladder and other parts of the urinary tract. According to the American Cancer Society there were over 76,000 new cases of bladder cancer diagnosed and over 15,000 deaths from advanced bladder cancer in the United States in 2014. At stage I, the 5-year survival rate is about 88% but at stage IV, the 5-year survival rate falls to 15%. Poor prognosis and ineffective therapies for patients with advanced bladder cancer make the discovery of new drugs very important for the treatment of this common disease.
In a pioneering study published last month in Molecular Cancer Therapeutics, researchers at Agensys Inc. identified the SLITRK6 protein as a new UCC biomarker and developed a novel antibody-drug conjugate (ADC) targeting SLITRK6 for the treatment of metastatic bladder cancer. Recent advances in the antibody-drug conjugate (ADC) technology and two recently approved ADCs have brought this drug class to the forefront of drug development in oncology.